These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 29355559)

  • 41. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
    BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen-Deprivation Therapy.
    Yamamoto S; Sakamoto S; Minhui X; Tamura T; Otsuka K; Sato K; Maimaiti M; Kamada S; Takei A; Fuse M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T
    Clin Genitourin Cancer; 2017 Dec; 15(6):e1107-e1115. PubMed ID: 28882738
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hormonal therapy of prostate cancer.
    Labrie F
    Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.
    Ross RW; Oh WK; Xie W; Pomerantz M; Nakabayashi M; Sartor O; Taplin ME; Regan MM; Kantoff PW; Freedman M
    J Clin Oncol; 2008 Feb; 26(6):842-7. PubMed ID: 18281655
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy.
    Pascal LE; Masoodi KZ; O'Malley KJ; Shevrin D; Gingrich JR; Parikh RA; Wang Z
    J Urol; 2015 Apr; 193(4):1388-93. PubMed ID: 25444984
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial.
    Antonarakis ES; Kibel AS; Yu EY; Karsh LI; Elfiky A; Shore ND; Vogelzang NJ; Corman JM; Millard FE; Maher JC; Chang NN; DeVries T; Sheikh NA; Drake CG;
    Clin Cancer Res; 2017 May; 23(10):2451-2459. PubMed ID: 27836866
    [No Abstract]   [Full Text] [Related]  

  • 47. Rapid androgen cycling as treatment for patients with prostate cancer.
    Feltquate D; Nordquist L; Eicher C; Morris M; Smaletz O; Slovin S; Curley T; Wilton A; Fleisher M; Heller G; Scher HI
    Clin Cancer Res; 2006 Dec; 12(24):7414-21. PubMed ID: 17189414
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
    Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C
    Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prolonging androgen sensitivity in prostate cancer - a role for COX inhibitors?
    Richards A; McGeechan K; Niknam M; Salomon R; Kurek C; Dong Q; Patel MI
    ANZ J Surg; 2009 Sep; 79(9):641-7. PubMed ID: 19895521
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
    Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
    BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.
    Dalrymple SL; Becker RE; Isaacs JT
    Prostate; 2007 May; 67(7):790-7. PubMed ID: 17373719
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator.
    Vajda EG; López FJ; Rix P; Hill R; Chen Y; Lee KJ; O'Brien Z; Chang WY; Meglasson MD; Lee YH
    J Pharmacol Exp Ther; 2009 Feb; 328(2):663-70. PubMed ID: 19017848
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alternative approaches to prevent androgen action in prostate cancer: are we there yet?
    Elbanna M; Heemers HV
    Discov Med; 2014 May; 17(95):267-74. PubMed ID: 24882718
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differential changes in luteinizing hormone secretion after administration of the investigational metastin/kisspeptin analog TAK-683 in goats.
    Endo N; Tamesaki C; Ohkura S; Wakabayashi Y; Matsui H; Tanaka A; Watanabe T; Okamura H; Tanaka T
    Anim Reprod Sci; 2015 Aug; 159():87-93. PubMed ID: 26051610
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effects of the concentration-dependent erythrocyte distribution of TAK-802, a potent acetylcholinesterase inhibitor, on rat pharmacokinetics.
    Kakehi M; Tagawa Y; Goto A; Kondo T; Asahi S
    Biopharm Drug Dispos; 2016 Nov; 37(8):467-478. PubMed ID: 27554287
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate.
    Colombel M; Filleur S; Fournier P; Merle C; Guglielmi J; Courtin A; Degeorges A; Serre CM; Bouvier R; Clézardin P; Cabon F
    Cancer Res; 2005 Jan; 65(1):300-8. PubMed ID: 15665307
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
    Nishiyama T; Hashimoto Y; Takahashi K
    Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
    Yamaoka M; Hara T; Hitaka T; Kaku T; Takeuchi T; Takahashi J; Asahi S; Miki H; Tasaka A; Kusaka M
    J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):115-28. PubMed ID: 22249003
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogenital tract.
    George FW
    Endocrinology; 1997 Mar; 138(3):871-7. PubMed ID: 9048585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.